When building your watch list, look for stocks with an 80 or higher RS Rating. MoonLake Immunotherap is one stock that just reached the mark, now earning a score of 85.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary rating measures share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating north of 80 as they begin their biggest price moves.
MoonLake Immunotherap is still within a buying range after moving past a 52.88 buy point in a cup with handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range.
The company posted 0% earnings growth in the latest quarterly report. Revenue rose 0%. Keep an eye out for the company's next round of numbers on or around Aug. 7.
The company earns the No. 199 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
